Literature DB >> 9712099

Patterns of cytokine production in psoriatic synovium.

C Ritchlin1, S A Haas-Smith, D Hicks, J Cappuccio, C K Osterland, R J Looney.   

Abstract

OBJECTIVE: To determine patterns of cytokine production and mRNA expression in synovium from patients with psoriatic arthritis (PsA) and to compare the profile of cytokine production in PsA explants with those derived from rheumatoid (RA) and osteoarthritic (OA) synovia and psoriatic skin.
METHODS: Cytokine levels were measured in supernatants from synovial and dermal explant cultures at Day 10 by ELISA. Cytokine mRNA expression in PsA whole tissue was determined by multi-gene assay. Cytokine levels in explant supernatants were compared between PsA, RA and OA, and psoriatic skin. Synovial tissues were scored histologically by a pathologist blinded to the clinical diagnosis.
RESULTS: PsA explants released elevated levels of interleukin (IL)-1beta, IL-2, IL-10, interferon (IFN)-gamma, and tumor necrosis factor (TNF)-alpha, but not IL-4 or IL-5. A similar pattern of gene expression was detected in whole synovial tissue. These cytokine levels were greater in PsA than RA, despite higher histopathologic scores in RA explants. Production of IL-1beta, IFN-gamma, and IL-10 were strongly correlated. Levels of IFN-gamma, IL-1beta, and IL-10 were higher in psoriatic synovium than psoriatic dermal plaques.
CONCLUSION: The cytokine profile in PsA is characterized by the presence of Th1 cytokines and the monokines TNF-alpha and IL-1beta and very elevated levels of IL-10. The higher levels of these cytokines in PsA compared to RA suggest the presence of different underlying mechanisms.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9712099

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  72 in total

Review 1.  Disease mechanisms in psoriasis and psoriatic arthritis.

Authors:  P Costello; O FitzGerald
Journal:  Curr Rheumatol Rep       Date:  2001-10       Impact factor: 4.592

Review 2.  Ankylosing spondylitis: introductory comments on its diagnosis and treatment.

Authors:  M A Khan
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

3.  TNFalpha therapy in psoriatic arthritis and psoriasis.

Authors:  P Mease
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

4.  Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.

Authors:  A Kavanaugh; G G Krueger; A Beutler; C Guzzo; B Zhou; L T Dooley; P J Mease; D D Gladman; K de Vlam; P P Geusens; C Birbara; D G Halter; C Antoni
Journal:  Ann Rheum Dis       Date:  2006-11-17       Impact factor: 19.103

5.  Preferential type 1 chemokine receptors and cytokine production of CD28- T cells in ankylosing spondylitis.

Authors:  C Duftner; C Dejaco; W Kullich; A Klauser; C Goldberger; A Falkenbach; M Schirmer
Journal:  Ann Rheum Dis       Date:  2005-10-11       Impact factor: 19.103

6.  Infliximab treatment in two patients with psoriatic arthritis and secondary IgA nephropathy.

Authors:  Grigorios T Sakellariou; Periklis Vounotrypidis; Charalampos Berberidis
Journal:  Clin Rheumatol       Date:  2006-08-19       Impact factor: 2.980

Review 7.  Clinical, radiological, and functional assessment in psoriatic arthritis: is it different from other inflammatory joint diseases?

Authors:  D D Gladman
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

8.  Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment.

Authors:  A W R van Kuijk; P Reinders-Blankert; T J M Smeets; B A C Dijkmans; P P Tak
Journal:  Ann Rheum Dis       Date:  2006-05-25       Impact factor: 19.103

Review 9.  Altered bone remodeling in psoriatic arthritis.

Authors:  Kofi A Mensah; Edward M Schwarz; Christopher T Ritchlin
Journal:  Curr Rheumatol Rep       Date:  2008-08       Impact factor: 4.592

Review 10.  Tumor necrosis factor-alpha in psoriasis and psoriatic arthritis: a clinical, genetic, and histopathologic perspective.

Authors:  David Kane; Oliver FitzGerald
Journal:  Curr Rheumatol Rep       Date:  2004-08       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.